MAPS· Kevin Cranford·AI score43
MAPS attends FDA public hearing on psychedelic drugs and plans written testimony on access and training
MAPS Attends Historic FDA Hearing on Psychedelics
AI summary
MAPS attended the FDA's September 14 public hearing on the potential future therapeutic use of psychedelic drugs and plans to submit written testimony on systems readiness.
Key facts
- Kind of item
- Guidance and consultations
- Compounds
- Psilocybin, MDMA, Ibogaine
- Organisation
- MAPS
- Regulator
- FDA (United States)
- Jurisdiction
- United States
- Source
- MAPS (maps.org)
- Published
- Original
- Read it at maps.org
How this summary was made
The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method
Source: MAPS · maps.org
Connected to
- Kind of item
- Guidance and consultations
- Compounds
- PsilocybinMDMAIbogaine
- Organisation
- MAPS
- Regulator
- FDA (United States)
- Jurisdiction
- United States